Abstract:Human cancer tissues are known to release their own DNA into body fluids such as plasma. These DNA molecules derived from tumors, collectively known as circulating tumor DNA (ctDNA), contain genetic information about disease progression at the time of sampling. Importantly, ctDNA has recently been utilized for capturing the whole-body disease profile and when sampled at various time points over the treatment, can inform the dynamic of clonal heterogeneity and its contribution to therapy failures. Metastatic castration-resistant prostate cancer (mCRPC) is a class of cancerous diseases with a high degree of clonal heterogeneity and high mortality which is largely due to the frequent emergence of therapy resistance. Therefore, reconstructing the clonal history for mCRPC diseases using ctDNA has great potential in identification of novel and targetable molecular mechanisms that drive mCRPC progression. To assess this possibility, we hypothesize that tumor clones that are responsible for therapy resistance carry distinct genomic profiles, which are captured in plasma ctDNA and could be computationally resolved through genomic sequencing and clonal reconstruction. To address this question, we obtained plasma cell-free DNA (cfDNA), a mixture of ctDNA and other tissue-derived DNA, from 38 individuals treated with combination PD-L1 and PARP inhibition involved in a recent clinical trial (NCT02484404). Whole-genome sequencing was performed using cfDNA and fragmented buffy coat DNA as germline control. cfDNA samples with a tumor fraction of lower than 10% were excluded. Various computational strategies were used to model the clonal structures of diseases and estimate the temporal order in which small and large structural variants emerged. Through this approach, we observed a negative association between cfDNA tumor fraction and therapy response. Multiple clonal evolutionary patterns leading to therapy failures were observed. For example, both gain and loss of activating androgen receptor mutations were detected in different cases following the treatment, which represents two distinct mechanisms of evading immunotherapy targeting. As a result, changes in the relevant transcriptional activities were also detected through ctDNA fragment-based computational inference. Additionally, clonal persistence was detected in multiple cases that exhibited stable diseases upon the treatment, which involves loss-of-function mutations in p53, ATM, and CDK12. To estimate the potential contribution to plasma ctDNA by metastatic diseases, multi-region whole genome and exome sequencing data of the tumors that are available for some cases prior to the treatment were also analyzed. Clones resolved from analyzing ctDNA were computationally mapped to the primary disease or metastatic tissue with a shared set of mutations in a subset of cases and may explain the patterns of treatment response. Our novel findings from this study will fill in a critical gap of knowledge about the complex genetic mechanisms driving mCRPC immunotherapy resistance. Citation Format: Chennan Li, Anna Baj, Clara C. Y. Seo, Nicholas T. Terrigino, John R. Bright, S. Thomas Hennigan, Isaiah M. King, Scott Wilkinson, Shana Y. Trostel, William D. Figg, William L. Dahut, Jung Min Lee, David Y. Takeda, Fatima Karzai, Adam G. Sowalsky. Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr PR005.

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer

Abstract PR005: Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

Genomic predictors of response and resistance to 177-Lu-PSMA-617 using circulating tumor DNA.

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Circulating Tumor-Dna Profiling to Reveal Heterogeneity of EGFR-TKI Resistance Mechanisms in Lung Adenocarcinoma Patients.

Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Abstract C034: Investigating residual disease in its spatial context in BRCA1 p53-deficient mammary tumors

Abstract C035: Spatially limited stroma-mediated resistance potentiates targeted therapy resistance through an integration of multiple juxtacrine and paracrine mechanisms

Abstract B005: Exploring breast cancer heterogeneity in the context of metastatic tumour microenvironments and therapy resistance

Abstract B015: CSF liquid biopsies reveal disease status and resistance mechanisms in children undergoing targeted therapy for malignant brain tumors

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Abstract 5850: Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in TNBC